Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802
US FDA clearance enables first-in-human study of PTD802, a selective GPR17 antagonist
Small molecule therapeutic designed to promote remyelination in neurological diseases such as multiple sclerosis
Milestone supports Pheno Therapeutics’ clinical development strategy
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company’s lead therapeutic candidate. The clearance allows Pheno to proceed with a first-in-human clinical trial of PTD802 in the US.
